Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Exposure to DMT may delay disability accumulation in primary progressive MS

Key clinical point: Longer exposure to DMT may delay time to EDSS 7 in patients with primary progressive MS.

Major finding: Compared with shorter exposure, longer exposure entailed a significantly lower risk of EDSS 7 (adjusted hazard ratio, 0.73).

Study details: A retrospective review of data for 1,214 patients with primary progressive MS in an Italian registry.

Disclosures: Study funding was not reported. Dr. Fonderico had no relevant disclosures.


Fonderico M et al. ECTRIMS 2020. Abstract PS05.03.